Comparison of Anti-Inflammatory Effects of Prednisolone versus Nepafenac 0.3% after Phacoemulsification and Intraocular Lens Implantation
Keywords:
Anti-Inflammatory Agents , Best-Corrected Visual Acuity, Non-Steroidal, Phacoemulsification, Postoperative Complications, Prednisolone AcetateAbstract
Objective: To compare the anti-inflammatory effects and safety profiles of prednisolone acetate 1% and nepafenac 0.3% in patients undergoing phacoemulsification with intraocular lens implantation (IOL).
Methods: This retrospective cross-sectional study was conducted at Sindh Institute of Ophthalmology and Visual Sciences, Hyderabad, Pakistan from December 2023 to July 2024. The study included patients underwent uneventful phacoemulsification with IOL implantation. Post-operative outcomes were assessed at a single follow-up conducted at 4 weeks. Primary efficacy endpoint was improvement in best-corrected visual acuity, measured as the reduction in Logarithmic Minimum angle of resolution (logMAR) values from baseline to follow-up. Clinically significant improvement was defined as a reduction of ≥0.2 logMAR units. Secondary outcomes included anterior chamber inflammation, graded using Standardization of Uveitis Nomenclature criteria, and incidence of adverse events.
Results: Of total 324 patients, mean age was 64.77 ±9.27 years. Mean logMAR change from baseline to follow-up was 0.28 ±0.11 units in the Prednisolone group and 0.30 ±0.11 units in the Nepafenac group, with statistically significant difference (p-value 0.050). The findings of clinical improvement, showed that 121 (48.8%) patients achieved clinical improvement in the Prednisolone group and 127 (51.2%) in the Nepafenac group. The distribution of inflammation grades (0, 1+, 2+, 3+), was similar between the Prednisolone and Nepafenac groups. A total of 76 (23.4%) adverse events were reported, with 40 (52.6%) occurring in the Prednisolone group and 36 (47.4%) in the Nepafenac group.
Conclusion: Both prednisolone acetate and nepafenac are effective and safe in managing post-operative inflammation and improving visual outcomes following phacoemulsification.
Downloads
References
Vision Loss Expert Group of the Global Burden of Diseas Study. Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020. Eye (Lond) 2024; 38:2156-72.
doi:10.1038/s41433-024-02961-1
Cicinelli MV, Buchan JC, Nicholson M, Varadaraj V, Khan-na RC. Cataracts. Lancet 2023; 401:377-89.
doi:10.1016/S0140-6736(22)01839-6
He L, Cui Y, Tang X, He S, Yao X, Huang Q, et al. Changes in visual function and quality of life in patients with senile cataract following phacoemulsification. Ann Palliat Med 2020 ; 9:3802-9.
doi:10.21037/apm-20-1709
Grzybowski A, Kanclerz P. Recent developments in cata-ract surgery. In : Current concepts in ophthalmology. Springer Cham 2020:e 55-97
doi: 10.21037/atm-2020-rcs-16
Seibel BS. Phacodynamics: mastering the tools and techniques of phacoemulsification surgery.4th ed, CRC Press; June 2024.
Benitez- Martinez M, Baeza- Moyano D, Gonzalez-Lezcano RA. Phacoemulsification: Proposals for improvement in its application. Healthcare (Basel) 2021; 9:1603.
doi:10.3390/healthcare9111603
El Haddad J, Al Sabbakh N, Macaron MM, Shaaban H, Bourdakos NE, Shi A, et al. NSAIDs and corticosteroids for the postoperative management of age-related cataract surger analysis. Am J Ophthalmol 2024; 260:1-13.
doi:10.1016/j.ajo.2023.09.027
Noyman DB, Chan CC, Mimouni M, Safir M. The efficacy and safety of standard versus soft topical steroids after cataract surgery: A Systematic Review and Meta-analysis. Ophthalmology 2024; 131:595-610.
doi:10.1016/j.ophtha.2023.11.022
Bezatis A, Georgou I, Dedes J, Theodossiadis P, Chatzirali I. Nepafenac in cataract surgery. Clin Exp Optom 2022; 105:263-7. doi:10.1080/08164622.2021.1945412
Ahmed S, Ghazanfar I, Niazi FA, Raza A. Role of Nepafe-nac 0.1% Ophthalmic Solution in Preventing Intraopera-tive Miosis during Phacoemulsification. Pak J Ophthalmol 2021; 37. doi:10.36351/pjo.v37i1.1038
Sarkar S, Bardoloi N, Deb AK. Comparison between 0.1% Nepafenac and 1% Prednisolone Eye Drop in Postoperative Management Following Micro-incisional Cataract Surgery. Korean J Ophthalmol 2021; 35:188-97. doi:10.3341/kjo.2020.0135
McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, et al. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC Ophthalmol 2017; 17:16. doi:10.1186/s12886-017-0405-7
Singhal D, Nanda A, Kanungo S, Sahoo K, nMohapatra S. A comparative analysis of topical corticosteroids and non-steroidal anti-inflammatory drugs to control inflammation and macular edema following uneventful phacoemulsificatio. Indian J Ophthalmol 2022; 70:425-33. doi:10.4103/ijo.IJO_1612_21
Nagpal M, Lambat S, Mehrotra N, Paranjpe G, Yadav H, Bhardwaj S. Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti- inflammatory agents in small gauge vitrectomy. Indian J Ophthalmol 2014; 62:606-9.doi:10.4103/0301-4738.12978
Donnenfeld ED, Holland EJ, Solomon KD. Safety and efficacy of nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery. J Cataract Refract Surg 2021; 47:158-64. doi:10.1097/j.jcrs.0000000000000414.
Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol 2009; 3:147-54.doi:10.2147/opth.s4684
Gayam K, Ramulu PY, Rengaraj V, Srinivasan K. Safety and efficacy of 0.1% Nepafenac versus 1% Prednisolone Acetate eye drops after laser peripheral iridotomy: A Prospective, Randomized Trial. Ophthalmol Glaucoma 2020; 3:174-80. doi:10.1016/j.ogla.2020.02.006.
Yuksel B, Karti O, Kusbeci T. Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives. Clin Ophthalmol 2017; 11:2183-90.doi:10.2147/OPTH.S132810
Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007; 33:53-8. doi:10.1016/j.jcrs.2006.08.043
Naithani P, Puranik S, Vashisht N, Khanduja S, Kumar S, Garg S. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery. Retina 2012; 32:250-5.doi:10.1097/IAE.0b013e31821e2057
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Adnan Abdul Majeed, Fariha Sher Wali, Waqas Ali, Mohsin Iqbal, Asra Talpur, Sajjad Ali Surhio
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. 
